DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant’s election without traverse of Group II, drawn to a method of treating a subject in recognized need of treatment for a disease or disorder responsive to NMDA modulation, and major depressive disorder as the elected disease or disorder responsive to NMDA modulation are maintained.
Status of Claims
Acknowledgement is made of the receipt and entry of the amendment to claims filed on July 1, 2026, wherein claims 1-47, 50 and 53-59 are canceled; claims 48-49 and 51-52 are amended; claims 60-71 are newly added.
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
Claims 48-49, 51-52 and 60-71 are pending.
Claims 48-49, 51-52, and 60-71 are under examination.
Priority
The instant application 17/621,907 filed on December 22, 2021 is a 371 of PCT/US2020/039163 filed on June 23, 2020, which claims priority to, and the benefits of U.S. Provisional Application No.
62/865,826 filed on June 24, 2019.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 7/1/2026 was filed after the mailing date of the Non-Final Office Action on April 1, 2026. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.
Action Summary
Claims 49 and 52 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement are withdrawn in view of the claim amendments. Specifically, the claim amendments delete the recitation of “3,” from the previous recitation of “having 3, 4 or 5 peaks”.
Claims 48-49 and 51-52 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement are maintained, but revisited and modified in view of the claim amendments.
Claims 48-49 and 51-52 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement are maintained, but revisited and modified in view of the claim amendments.
Claims 48-49 and 51-52 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention are withdrawn in view of the claim amendments.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 60 and 66 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement (newly applied as necessitated by amendment). The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016.
In this case, newly added claims 60 and 66 promise a broad solid form genus of compound A exhibiting powder X-ray diffraction peaks at the three positions instantly claimed.
The specification expressly describes solid state forms can be crystalline (wherein the molecules of the solid form are arranged in a long-range regularly repeating crystal lattice which can be described by a unit cell) or amorphous (wherein the molecules of the solid form are not arranged in any significant regularly repeating manner) (se e.g., [00100]). Therefore, Applicant’s own disclosure contemplates a genus of distinct solid form of compound A, including crystalline and amorphous forms.
In contrast, the specification does not reasonably convey to one of ordinary skill in the art that Applicant was in possession of the full scope of the claimed solid form of compound A coupled with the claimed peaks. The instant specification discloses only two solid crystalline species of compound A, which are Crystalline Form I of compound A and Crystalline Form II of compound A; and one amorphous form of Compound A. Specifically, the specification expressly describes a crystalline form I of compound A in Example 1 with a X-ray powder diffraction pattern shown in Fig. 1; describes a crystalline form II of compound A in Example 2 with a X-ray powder diffraction pattern shown in Fig. 3; and describes one amorphous form of Compound A in Example 3 (prepared by dissolving crystalline Form 1 of Compound A in 10 mL acetone) with an XRPD shown in Fig. 7, and that only has one main broad peak.
In other words, the disclosure demonstrates the amorphous form of compound A does not retain any of the powder X-ray diffraction peaks instantly claimed. While applicant is in possession of the Crystalline Form I of compound A and Crystalline Form II of compound A noted above, the specification fails to identify any other particular solid form species of compound A coupled with their physical properties. Although applicant does not have to exemplify each and every possible species of solid form of compound A to satisfy the written description requirement, applicant needs to provide enough representative species from different corners of the range to represent the claimed genus fairly. Since the instant claim pertains to a solid form genus, including a wide variety of amorphous solids and crystalline solids with different physical properties, applicant must provide a reasonable sampling of them couples with their physical properties so that a relevant artisan can see applicant truly envisioned the whole genus.
Accordingly, there is lack of sufficient variety of solid form species to reflect the variation within the claimed genus to reasonably convey to a person skill in the art that applicant was in possession of the entire solid form genus of compound A exhibiting the claimed powder X-ray diffraction peaks.
Response to Arguments
Applicant's arguments filed on July 1, 2026 with respect to the rejection of claims 49 and 52 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement have been fully considered but they are not persuasive.
In Summary, applicant argues claims 49 and 52 now deletes the recitation of “3” from the previous phrase of “having 3, 4 or 5 peaks (2θ)”, and that overcomes the rejection of record. Applicant further argues newly added claims 60 and 66 recited the three most intense peaks corresponding to the X-ray powder diffraction pattern in Figures 1 and 3, respectively; and these 3 recited peaks are sufficient to define the unique fingerprint of this crystal.
In response, applicant’s arguments are not found persuasive for the reasons set forth below:
First, applicant’s arguments with respect to claims 49 and 52 are moot, because these claims has been amended by deleting the recitation of “3” peaks; However, applicant’s arguments with respect to newly added claims 60 and 66 are not found persuasive, because these claims do not recite a solid “crystalline” form of compound A; instead, these claims broadly recites “a solid form of compound”. As noted in the instant rejection, the specification expressly describes solid state forms can be crystalline or amorphous, and that contemplates a genus of distinct solid forms of compound A.
A person skilled in the art would recognize that different solid forms of the same chemical formula (i.e., Compound A) can exhibits different physical and chemical properties due to polymorphism, different stoichiometric ratios, or varying internal arrangement; and that two crystalline species disclosed by Applicant is not representative of the claimed genus, which embraces vast variety of solid forms, including crystalline and amorphous forms, with any distinct properties. Since applicant only describe two crystalline species and one amorphous species that clearly does not have the claimed peaks, it demonstrates that there may be unpredictability in the results obtained from species other than those specifically enumerated.
Given that the claimed genus contains substantial variation of solid forms, the disclosed species does not resolve the written description inquiry as these species are not sufficient to represent the full solid form genus couple by their physical properties as broadly encompassed by instant claims.
While applicant is in possession of the Crystalline Form I or Crystalline Form II, the newly added claim(s) only recite three powder X-ray diffractions peaks, and they are not sufficient to identify these specific cocrystal species. In other words, having a sufficient number of peaks in the X-ray powder diffraction pattern is often required for one of ordinary skill in the art to distinguish the cocrystal species. That being said, instant claim(s) are drawn to a genus of distinct solid forms that lack adequate description support; thus, applicant’s arguments are not found persuasive.
Therefore, the rejection has been applied to newly added claims as necessitated by amendments.
Claims 48-49 and 51-52 remain rejected and claims 60-71 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention (partially newly applied as necessitated by amendment).
Instant amended claims 48, 49, 51 and 52, and newly added claims 60 and 66 broadly recites a method of treating major depressive disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and a solid form of compound A.
In short, the solid form of compound A of claims 48 and 49 are each drawn to a solid crystalline Form I of compound A, in which claim 48 recites the orthorhombic crystal system and unit cell dimensions, whereas claim 49 recites 4 or 5 peaks in the powder X-ray diffraction pattern. The solid form of compound A of claims 51 and 52 are each drawn to a solid crystalline Form II of compound A, in which claim 51 recites the orthorhombic crystal system and unit cell dimensions, whereas claim 52 recites 4 or 5 peaks in the powder X-ray diffraction pattern. The solid form of compound A of claim 60 is to the one that exhibiting powder X-ray diffraction peaks at 10.3±0.2, 13.7±0.2, and 18.5±0.2. The solid form of compound A of claim 66 pertains to the one that exhibiting powder X-ray diffraction peaks at 11.9 ± 0.2, 15.5 ± 0.2, and 21.3 ± 0.2.
There is insufficient written basis for “a therapeutically effective amount”, “a subject”, and “administering” in the specification. There is also lack of representative number of method species for treating the full scope of subject in recognized need of treatment for major depressive disorder.
The Written Description Guidelines for examination of patent applications indicates, “the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical characteristics and/or other chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show applicant was in possession of the claimed genus.” (Federal register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001, see especially page 1106 column 3) and (see MPEP §2164). A “representative number of species” means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. The disclosure of only one species encompassed within a genus adequately describes a claim directed to that genus only if the disclosure “indicates that the patentee has invented species sufficient to constitute the gen[us].” See Enzo Biochem, 323 F.3d at 966, 63 USPQ2d at 1615; Noelle v. Lederman, 355 F.3d 1343, 1350, 69 USPQ2d 1508, 1514 (Fed. Cir. 2004).
Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. v. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016.
One cannot describe what one has not conceived. See Fiddles v. Baird, 30 USPQ2d 1481, 1483. In Fiddles v. Baird, claims directed to mammalian FGF’s were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence. Thus, the specification fails to describe these DNA sequences. The Court further elaborated that generic statements are not adequate written description of the genus because it does not distinguish the claimed genus from others, except by function.
In the present case, applicant amends the claims by adding the limitation of “, and wherein the therapeutically effective amount is an amount sufficient to alleviate, abate, or otherwise reduce a symptom of major depressive disorder”, such that the claimed term “therapeutically effective amount” no longer includes prevention from the specifical definition recites in paragraph [0095] of the specification. Applicant does not describe how the pharmaceutical composition is being administered (e.g., route of administration) to the subject; and also fails to describe what subject in need thereof is receiving the pharmaceutical composition. There is also no representative number of method species describing the claimed genus. The only factor present in the claims is a recitation that any therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the claimed solid form of compound A can be used for treating a subject in recognized need of treatment for major depressive disorder. Thus, in the absence of sufficient representative number of method species, applicant has not provided sufficient written description that would reasonably convey to one skilled in the relevant art that the applicant was actually in the possession of the entire scope of administering any therapeutically effective amount of the pharmaceutical composition through any route of administration to each and every subject species for alleviating, abating, or reducing the severity of a symptoms of major depressive disorder.
Response to Arguments
Applicant's arguments filed on July 1, 2026 with respect to the rejection of claims 48-49 and 51-52 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement have been fully considered but they are not persuasive.
In this case, applicant amends claims 48-49 and 51-52 by adding the new limitation of “, and wherein the therapeutically effective amount is an amount sufficient to alleviate, abate, or otherwise reduce a symptom of major depressive disorder”; and further changes the previous recitation of “[a] method of treating a subject in recognized need of treatment for major depressive disorder, comprising administering to said subject in need thereof a therapeutically effective amount…” to the recitation of “[a] method of treating major depressive disorder in a subject in need thereof, comprising administering a therapeutically effective amount…”. Applicant also newly added claims 60-71, and that changes the scope of the claims and necessitates a modification of the rejection of record.
In Summary, applicant argues the amendments now limit the scope of the claims to the treatment of major depressive disorder and removes prevention from the definition of therapeutically effective amount; and these amendments overcomes the rejection of record.
In response, applicant’s arguments are not found persuasive. The mere fact that the amendments limit the scope of the claims does not resolve the written description inquiry, because the deficiency is that the claimed method genus encompassed substantial method variation resulting from the independent selection and combination of administration route, subject, and a therapeutically effective amount, whereas the specification provides no species to reasonably represent the diversity encompassed by these method genus.
In other words, the disclosure does not describe sufficient variety of administration routes, subjects, and therapeutically effective amounts of the claimed pharmaceutical composition encompassed by the method genus that allows a person skilled in the art to visualize or recognized the entire scope of the method of treating major depressive disorder. The disclosure does not describe an actual reduction to practice of the claimed invention. For instance, simply using functional language to describe what a therapeutically effective amount does (i.e., “an amount sufficient to alleviate, abate, or otherwise reduce a symptom of major depressive disorder”) in the method genus does not established what the amount is as a person skilled in the art would have to perform testing to determine the optimal amount in order to established correlation between the amount and the claimed function of treating major depressive disorder.
Therefore, applicant’s arguments are not found persuasive. The rejection of record has been maintained but revisited and modified in view of the claim amendments for the same reasons of record and for the reasons set forth herein.
Claims 48-49 and 51-52 remain rejected and claims 60-71 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention (partially newly applied as necessitated by amendment).
Attention is directed to in re Wands, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex parte Forman, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors: (1) the nature of the invention; (2) the state of the prior art; (3) the relative skill of those in the art; (4) the predictability or unpredictability of the art; (5) the breadth of the claims; (6) the amount of direction or guidance presented; (7) the presence or absence of working examples; and, (8) the quantity of experimentation necessary. All of the Wand’s factors have been considered and discussed below:
(1, 5) The breadth of the claims and the Nature of the Invention: As stated in MPEP 2164.05(a), “[t]he initial inquiry” for determining whether the Specification is enabling “is into the nature of the invention, i.e., the subject matter to which the claimed invention pertains.”
Instant amended claims 48, 49, 51 and 52, and newly added claims 60 and 66 broadly recites a method of treating major depressive disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and a solid form of compound A.
In short, the solid form of compound A of claims 48 and 49 are each drawn to a solid crystalline Form I of compound A, in which claim 48 recites the orthorhombic crystal system and unit cell dimensions, whereas claim 49 recites 4 or 5 peaks in the powder X-ray diffraction pattern. The solid form of compound A of claims 51 and 52 are each drawn to a solid crystalline Form II of compound A, in which claim 51 recites the orthorhombic crystal system and unit cell dimensions, whereas claim 52 recites 4 or 5 peaks in the powder X-ray diffraction pattern. The solid form of compound A of claim 60 is to the one that exhibiting powder X-ray diffraction peaks at 10.3±0.2, 13.7±0.2, and 18.5±0.2. The solid form of compound A of claim 66 pertains to the one that exhibiting powder X-ray diffraction peaks at 11.9 ± 0.2, 15.5 ± 0.2, and 21.3 ± 0.2.
The claimed term “a therapeutically effective amount” recites therein is reasonably constructed in view of the newly added limitation “, and wherein the therapeutically effective amount is an amount sufficient to alleviate, abate, or otherwise reduce a symptom of major depressive disorder”.
In view of the foregoing, the breath of these claims pertains to administering a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the full scope of solid form of compound A having the claimed characteristics for treating the full scope of major depressive disorder in a subject in need thereof.
(2, 3, 4) The state of the prior art, the level of skill in the art, and the predictability or lack
thereof in the art: As stated in MPEP 2164.05(a), “[t]he state of the prior art is what one skilled in the
art would have known, at the time the application was filed, about the subject matter to which the
claimed invention pertains” and, as stated in MPEP 2164.05(b), “[t]he relative skill of those in the art
refers to the skill of those in the art in relation to the subject matter to which the claimed invention
pertains at the time the application was filed.”
At the time the application was filed, one skilled in the art would have known tert-butyl (S)-2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro [3.4]octane-5-carboxylate having the structure of:
PNG
media_image1.png
101
150
media_image1.png
Greyscale
is a white solid, and obtained as an intermediate during the synthesis of compound B having the structure of:
PNG
media_image2.png
127
163
media_image2.png
Greyscale
that is NMDA modulator according to Khan et al. (WO 2017/201283 A1; cited in the Office Action mailed on February 20, 2025) (see e.g., p. 34, “Example 2 - Synthesis of Compound B and Compound B Maleic Acid Salt”; p. 38, line 18 to p. 39, line 4; p. 3, line 4-10). Please note tert-butyl (S)-2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro [3.4] octane-5-carboxylate of Khan et al. is referred to as compound “B4” in the cited reference whereas the instant application referred to as “compound A". It is noted that Khan et al. does not disclose the utility and the biological or pharmaceutical activity of said intermediate; and Khan et al. does not disclose a solid crystalline form species of said intermediate or powder X-ray diffraction peaks of said intermediate. In other words, one skilled in the art would have known tert-butyl (S)-2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro [3.4] octane-5-carboxylate is an intermediate and a temporary species formed during a chemical reaction.
At the time the application was filed, one skilled in the art would have known compound 2S-FNL-2, tert-butyl 2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate, having the structure of
PNG
media_image3.png
206
210
media_image3.png
Greyscale
is an exemplary compound represent by formula I that are NMDA modulators (e.g., partial agonists of NMDA) according to Lowe, III et al. (WO 2014/120783 A1; cited in the IDS filed on March 22, 2022) (see e.g., [008]; [0091]; p. 29, Table 1, “2S-FNL-2”; p. 74). While 2S-FNL-2 of Lowe, III et al. shares the structural similarity, one skilled would have known the compound 2S-FNL-2 of Lowe, III et al. is not tert-butyl (S)-2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro [3.4] octane-5-carboxylate because it contains 2 chiral centers rather than 3 chiral centers.
One of ordinary skill in the art would have known intermediates serve as building blocks in early stage of production, undergoing various chemical transformations to eventually produce the active pharmaceutical ingredients (APIs). Intermediate are temporary, transitional compounds used to create APIs, but do not have therapeutic properties on their own; and they often require specific storage as they may have shorter lifespans according to SimSon Pharma Limited (“What Are Intermediates in Pharma|APIs vs Intermediates” [Online]. Published on November 18, 2024) (see e.g., p. 1; p. 3, “function and purpose”). In other words, the relative skill of those in the art using an intermediate as an active pharmaceutical ingredient would have been low, because there is lack of predictability as to whether an intermediate can possess therapeutic properties without any further testing.
One of ordinary skill in the art would have also known a difference in a single stereocenter can have dramatic effects on biological activity for natural products and FDA-approved drugs, for example, 1,4-dihydropyrans are ligands of L-type calcium channel that exhibit stereoselectivity for the type of activity; and the S-enantiomer is an activator of the channel and the R-enantiomer is an inhibitor of the channel, according to Scott et al. (Current Research in Chemical Biology, 2022. Vol. 2: 100028). Therefore, the cited reference demonstrates there is lack of predictability that tert-butyl (S)-2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro [3.4] octane-5-carboxylate, which contains additional stereocenter compared to 2S-FNL-2 of Lowe, III et al., would successfully modulate NMDR.
According to FirstWord Pharma (“Top Story Allergan's rapastinel fails to meet primary endpoints in Phase III depression studies” [Online]. Published on March 6, 2019), the results from the Phase III RAP-MD-01, RAP-MD-02 and RAP-MD-03 studies of the major depressive disorder drug candidate rapastinel, a modest and selective positive NMDA receptor modulator, saying treatment arms did not differentiate from placebo on the primary and key secondary endpoints; and an interim analysis of rapastinel in the RAP-MD-04 relapse prevention study suggests the primary and key secondary endpoints will not be met either (see e.g., page 1). The cited reference demonstrates there is lack of predictability in the art for treating major depressive disorder.
Therefore, based upon the cited references, it is uncertain whether administering the full scope of a therapeutic effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the full scope of a solid form of compound A with the claimed characteristic(s) can successfully treat major depressive disorder in any subject in need.
(6, 7, 8) The amount of guidance given, the presence of working example and the quantitation
of experimentation required:
In view of all the foregoing, at the time the application was filed, it would have required undue experimentation to practice the entire scope of the claimed invention. The specification only describes the method of preparing the solid crystalline form I of compound A and solid crystalline form II of compound A; and does not disclose their biological activities nor exemplify the administration of said solid crystalline form in the working examples. Based on the limited disclosure, the relative skill of those in the art could not reasonably predict whether the solid crystalline form of tert-butyl (S)-2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro [3.4]octane-5-carboxylate, which is known to be an intermediate for synthesizing the active pharmaceutical ingredient, could successfully treat the entire scope of major depressive disorder in any subject in need thereof without confirming their biological or pharmaceutical activity. Therefore, it would require undue experimentations as it is highly unpredictable that the administration any therapeutic effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the claimed solid crystalline form of tert-butyl (S)-2-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-oxo-2,5-diazaspiro [3.4]octane-5-carboxylate (Compound A) would, in fact, be usable across the entire scope of subject in need of treatment for major depressive disorder.
Accordingly, the method of treating the full scope major depressive disorder in any subject in need thereof, comprising administering any therapeutically effective amount of the full scope of pharmaceutical composition comprising a pharmaceutical acceptable carrier and the solid crystalline form of compound A with the claimed characteristics are not enabled by the specification.
This is a full enablement rejection.
Response to Arguments
Applicant's arguments filed on July 1, 2026 with respect to the rejection of claims 48-49 and 51-52 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement have been fully considered but they are not persuasive.
In this case, applicant amends claims 48-49 and 51-52 by adding the new limitation of “, and wherein the therapeutically effective amount is an amount sufficient to alleviate, abate, or otherwise reduce a symptom of major depressive disorder”; and further changes the previous recitation of “[a] method of treating a subject in recognized need of treatment for major depressive disorder, comprising administering to said subject in need thereof a therapeutically effective amount…” to the recitation of “[a] method of treating major depressive disorder in a subject in need thereof, comprising administering a therapeutically effective amount…”. Applicant also newly added claims 60-71, and that changes the scope of the claims and necessitates a modification of the rejection of record.
In Summary, applicant argues the claim amendments overcomes the rejection of record by changing the preamble of claims 48-49 and 51-52, and removing the prevention from the definition of a “therapeutically effective amount”. Applicant further argues the claimed invention is supported by the teachings of Burgdof et al. (International Journal of Neuropsychopharmacology, 2022. Vol. 25, Issue 12: 979-991; cited in the IDS filed on July 1, 2026). Specifically, applicant cited the statement of “a novel, orally bioavailable NMDAR allosteric modulator that binds to a unique site on NMDAR, is currently in phase 2 development for the treatment of MDD. We report here that orally administered zelquistinel exhibits a favorable safety/tolerability profile and can rapidly and persistently enhance activity-dependent long-term synaptic plasticity, accompanied by a rapid-acting and long-lasting antidepressantlike effects in rodents” (see e.g., p. 980, “Significance Statement” section, line 5-9) in Burgdof et al. to support the enablement of the claimed invention; and therefore, at the time of filing, the amended claims are supported by the submitted post-filing data.
In response, applicant’s arguments are not found persuasive for the reasons set forth below:
It is respectfully noted that the rejection of record does not rely on teachings of Burgdof et al. to form the basis of rejection. However, Burgdof et al. submitted in the IDS filed on July 1, 2026 (after the mailing date of the Non-Final Office Action on April 1, 2026) have been fully considered by the Examiner. While the behavior studies disclosed by Burgdof et al. demonstrates oral administration of Zelquistinel, which is synthesized in free-based form by Sai Life Sciences (Hyderabad, India), dissolved in 0.9% sterile saline (see e.g., p. 980, right column, “Materials and Methods” section, 1st paragraph under “Animals”) at the dose of 30 μg/kg to rats produced antidepressant-like activity in the Force Swim Test; However, Burgdof et al. discloses the rapid antidepressant-like effects in the rat forced swim test is dose-dependent (see e.g., Figure 6); and particularly noted that the doses > 100 μg/kg were less effective (see e.g., p. 982, left column, “Force Swim Test (FST)”; p. 989, left column, 2nd paragraph; Fig. 6). In other words, it may well be true that the animal behavior studies performed by Burgdof et al. demonstrates oral administration of 30 μg/kg of Zelquistinel dissolved in 0.9% sterile saline to rats exhibits antidepressant-like effects in the force swim test, and is in phase 2 development for the treatment of major depressive disorder: However, the data disclosed by Burgdof et al. which applicant relies upon does not established enablement for the claimed solid crystalline Form I of compound A, the claimed solid crystalline Form II of compound A, or the claimed solid form of compound A, because the disclosure of Burgdof et al. does not identify the claimed solid crystalline Form I-II of compound A or a solid form of compound A by powder X-ray diffraction peaks, orthorhombic crystal system (P212121 space group), unit cell dimensions, differential scanning calorimetry (DSC), polymorphic designation, crystal structure, or other crystalline characteristics. In other words, while the disclosure of Burgdof et al. provides data for Zelquistinel in animal studies, it does not establish the claimed solid crystalline form, or the claimed solid form was presented in the materials administered in these animal studies.
Additionally, the results presented by Burgdof et al. are not commensurate in scope with the claimed invention. It is respectfully noted that Burgdof et al. expressly teaches zelquistinel was dissolved in 0.9% sterile saline and administered orally to rats and discloses that the antidepressant-like effect is dose dependent. In contrast, instant claims require “a solid form of compound A”, broadly encompassed any administration route, any subject, and any therapeutically effective amount sufficient to alleviate, abate, or otherwise reduce a symptom of major depressive disorder. In other words, the results presented by Burgdof et al. do not occur over the entire claimed range and fail to provide adequate basis for concluding that similar results would be obtained for the claimed solid form, other administration routes (e.g., intravenous), and other subjects (e.g., human).
Lastly, according to MPEP 2164.05 with respect to Determination of Enablement Based on Evidence as a Whole, “[t]o overcome a prima facie case of lack of enablement, applicant must present argument and/or evidence that the disclosure would have enabled one of ordinary skill in the art to make and use the claimed invention at the time of filing. This does not preclude applicant from providing a declaration after the filing date which demonstrates that the claimed invention works. However, the examiner should carefully compare the steps, materials, and conditions used in the experiments of the declaration with those disclosed in the application to make sure that they are commensurate in scope; i.e., that the experiments used the guidance in the specification as filed and what was well known to one of skill in the art at the time of filing. Such a showing also must be commensurate with the scope of the claimed invention, i.e., must reasonably enable the full scope of the claimed invention. See Pac. Biosciences of Cal., Inc. v. Oxford Nanopore Techs., Inc., 996 F.3d 1342, 1352, 2021 USPQ2d 519 (Fed. Cir. 2021) (The court found that undue experimentation was required to enable the full scope of the claims where there was ample evidence that relevant artisans would not know how to perform the claimed invention for more than a narrow range of the claimed scope of invention. Moreover, there was no evidence of actual reduction to practice to support patentee’s rebuttal of the lack of enablement determination)”.
In this case, Applicant submitted Burgdof et al. published on July 26, 2022, which is after the effective filing date of instant application, as the post-filing evidence to overcome a prima facie case of lack of enablement, such data was not in the form of a declaration. Additionally, the experiment conducted post-filing cannot be used to establish the state of the art at the time the application was filed, nor to supply missing technical teachings that the original specification needed. According to MPEP 716.09, “[e]vidence to supplement a specification which on its face appears deficient under 35 U.S.C. 112 must establish that the information which must be read into the specification to make it complete would have been known to those of ordinary skill in the art. In re Howarth, 654 F.2d 103, 210 USPQ 689 (CCPA 1981)”. As noted in the rejection of record, the specification originally presented provides no working examples demonstrating the administration of the claimed solid form of Compound A in the pharmaceutical composition at any sufficient amount for treating major depressive disorder at the time of filing, thus, the post-filing evidence cannot support sufficiency of disclosure.
In view of the foregoing, applicant’s arguments are not found persuasive; therefore, the rejection of record has been maintained, but revisited and modified in view of the claim amendments for the same reasons of record and for the reasons set forth herein.
Conclusion
No claims are allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chihyi Lee whose telephone number is (571)270-0663. The examiner can normally be reached Monday - Friday 8:30 am - 5:00 pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached at (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/CHIHYI LEE/Examiner, Art Unit 1628 /JEAN P CORNET/Primary Examiner, Art Unit 1628